

Exhibit No.	Reference
1001	U.S. Patent No. 9,464,140 to Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, and Michael C. Milone, issued October 11, 2016 (“the ’140 patent”)
1002	Expert Declaration of Richard Paul Junghans (Dated April 8, 2022)
1003	U.S. Patent Application Publication No. 2005/0113564 to Dario Campana and Chihaya Imai, published May 26, 2005 (“Campana”)
1004	Ian C. Nicholson et al., <i>Construction and Characterisation of a Functional CD19 Specific Single Chain Fv Fragment for Immunotherapy of B Lineage Leukaemia and Lymphoma</i> , 34 MOLECULAR IMMUNOLOGY 1157 (1997) (“Nicholson”)
1005	U.S. Patent No. 4,844,893 to Cyril J. Honsik and Ralph A. Reisfeld, issued July 4, 1989 (“Honsik”)
1006	Duncan Hall Decl. for <i>Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma (CART-19)</i> , CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT00891215 [https://web.archive.org/web/20090507184629/https://clinicaltrials.gov/ct2/show/NCT00891215 (May 07, 2009)] (“CART-19 ClinicalTrials.gov”)
1007	U.S. Patent Application Publication No. 2004/0126363 to Michael C. Jensen, Stephen Forman, and Andrew Raubitschek, published July 1, 2004 (“Jensen”)
1008	Michael C. Milone et al., <i>Chimeric Receptor Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo</i> , 17 MOLECULAR THERAPY 1453 (2009) (“Milone”)
1009	Dan R. Littman et al., <i>The Isolation and Sequence of the Gene Encoding T8: A Molecule Defining Functional Classes of T Lymphocytes</i> , 40 CELL 237 (1985) (“Littman”)
1010	U.S. Patent Application No. 2004/0043401 to Michel Sadelain, Renier Brentjens, and John Maher, published March 4, 2004 (“Sadelain”)
1011	<i>Reserved</i>
1012	David L. Porter et al., <i>Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia</i> , 365 N. ENGL J. MED. 725 (2011), and Protocol for Porter et al. (“Porter”)

Exhibit No.	Reference
1013	Protocol for David L. Porter et al., <i>Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia</i> , 365 N. ENGL J. MED. 725 (2011)
1014	<i>Reserved</i>
1015	<i>Reserved</i>
1016	<i>Reserved</i>
1017	<i>Reserved</i>
1018	Excerpts from File History of PCT/US2011/064191, filed December 9, 2011
1019	File History of U.S. Provisional Application 61/502,649, filed June 29, 2011 (“the ’649 application”)
1020	File History of U.S. Provisional Application 61/421,470, filed December 9, 2010 (“the ’470 application”)
1021	Excerpts from File History of the ’140 patent
1022	C. Imai & D. Campana, <i>Chimeric Receptors with 4-1BB Signaling Capacity Provoke Potent Cytotoxicity Against Acute Lymphoblastic Leukemia</i> , 18 LEUKEMIA 676 (2004) (“Imai”)
1023	Ng and Henikoff, <i>SIFT: Predicting Amino Acid Changes That Affect Protein Function</i> , 31 NUCLEIC ACIDS RSCH. 3812 (2003) (“Ng”)
1024	Nathaniel E. Frank-White Decl. for <i>Sorting Intolerant From Tolerant</i> , N. ENGL. J. MED., http://blocks.fhrc.org/blocks/ [https://web.archive.org/web/20130728182255/http://blocks.fhrc.org/blocks/ (Nov. 18, 2008)]
1025	Salvatore J. Turco, <i>Intravaneous Admixtures</i> , in 18 REMINGTON’S PHARMACEUTICAL SCIENCES 1570 (Alfonso R. Gennaro ed., 1990) (“Turco”)
1026	<i>Reserved</i>
1027	<i>Corrections</i> , 374 N. ENGL J. MED. 998 (2016)
1028	Excerpts from File History of U.S. Patent Application No. 15/353,899 (“the ’899 application”)
1029	Excerpts from KENNETH MURPHY ET AL., <i>JANEWAY’S IMMUNOBIOLOGY</i> (7th ed. 2008) (“Immunobiology”)
1030	Excerpts from BRUCE ALBERTS ET. AL., <i>MOLECULAR BIOLOGY OF THE CELL</i> (4th ed. 2002) (“Molecular Biology”)
1031	Bipulendu Jena et al., <i>Redirecting T-cell Specificity by Introducing a Tumor-Specific Chimeric Antigen Receptor</i> , 116 BLOOD 1035 (2010) (“Jena”)

Exhibit No.	Reference
1032	Christopher A. Klebanoff et al., <i>Sinks, Suppressors and Antigen Presenters: How Lymphodepletion Enhances T Cell Mediated Tumor Immunotherapy</i> , 26 TRENDS IMMUNOL. 111 (2005) (“Klebanoff”)
1033	James S. Huston et al., <i>Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia coli</i> , 85 PROC. NAT’L ACAD. SCI. 5879 (1988) (“Huston”)
1034	R.D. Mosteller, <i>Simplified Calculation of Body-surface Area</i> , 317 N. ENGL. J. MED. 1098 (1987) (“Mosteller”)
1035	Margaret A. McDowell et al., Nat’l Ctr. For Health Stat., <i>Anthropometric Reference Data for Children and Adults: United States, 2003–2006</i> , NAT’L HEALTH STAT. REPS., October 22, 2008 (“McDowell”)
1036	Jean Philippe Boursier et al., <i>Evidence for an Extended Structure of the T-cell Co-receptor CD8a as Deduced from the Hydrodynamic Properties of Soluble Forms of the Extracellular Region</i> , 268 J. BIOLOGICAL CHEMISTRY 2013 (1993) (“Boursier”)
1037	Vikas P. Sukhatme, <i>The T Cell Differentiation Antigen Leu-2/T8 Is Homologous to Immunoglobulin and T Cell Receptor Variable Regions</i> , 40 CELL 591 (1985) (“Sukhatme”)
1038	<i>CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy</i> , CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/NCT01029366 (last visited April 2022)
1039	Nathaniel E. Frank-White Decl. for David L. Porter et al., <i>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia</i> , N. ENGL. J. MED. (Aug. 25, 2011), https://www.nejm.org/doi/full/10.1056/NEJMoa1103849 [https://web.archive.org/web/20110924175244/http://www.nejm.org/doi/full/10.1056/NEJMoa1103849 (Sept. 24, 2011)]
1040	Nathaniel E. Frank-White Decl. for David L. Porter et al., <i>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia</i> , N. ENGL. J. MED. (Aug. 25, 2011), https://www.nejm.org/doi/full/10.1056/NEJMoa1103849 [https://web.archive.org/web/20120422111453/http://www.nejm.org:80/doi/full/10.1056/NEJMoa1103849 (April 22, 2012)]
1041	Excerpts from File History of U.S. Patent No. 8,911,993

Exhibit No.	Reference
1042	Ulrich Schneider et al., <i>Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma</i> , 19 INT. J. CANCER 621 (1977) (“Schneider”)
1043	Yangbing Zhao et al., <i>Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor</i> , 70 CANCER RSCH. 9053 (2010) (“Zhao”)
1044	<i>Reserved</i>
1045	James N. Kochenderfer et al., <i>Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19</i> , 116 BLOOD 4099 (“Kochenderfer 2010”)
1046	Renier J. Brentjens et al., <i>Phase I Trial for the Treatment of Chemo-Refractory Chronic Lymphocytic Leukemia with CD19-Targeted Autologous T Cells</i> , 16 MOLECULAR THERAPY S15 (2008) (“Brentjens”)
1047	Marco L. Davila et al., <i>B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen</i> , 116 BLOOD Abstract 3268 (2010) (“Davila”).
1048	James N. Kochenderfer, <i>Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor</i> , 32 J. IMMUNOTHERAPY 689 (2009) (“Kochenderfer 2009”)
1049	<i>Reserved</i>
1050	David Mead et al., <i>Recombinant Human Albumin: Applications as a Biopharmaceutical Excipient</i> , 22 INNOVATIONS PHARM. TECH. 42 (2007) (“Mead 2007”)
1051	<i>Reserved</i>
1052	Attorney Declaration of Monica M. Arnold

Certificate

I hereby certify, pursuant to 37 C.F.R. Sections 42.6 and 42.105, that a complete copy of the attached Exhibit List, including related documents, are being served via Priority Mail Express on the eleventh day of April, the same day as the filing of the above-identified document in the United States Patent and Trademark Office/Patent Trial and Appeal Board, upon the patent owner by serving the correspondence address of record with the USPTO as follows:

Kathryn Doyle & Patent Docket Clerk

Saul Ewing Arnstein & Lehr LLP

Centre Square West

1500 Market Street, 38th Floor

Philadelphia PA 19102-2186).

DATED: April 11, 2022

/Yite John Lu /

Yite John Lu

Reg. No. 63158

Milbank LLP

2029 Century Park East, 33rd Floor

Los Angeles, CA 91167

Tel. (424) 386-4318

Fax. (213) 629-5063

jlu@milbank.com

Counsel for Petitioner